| |
Latest 10 SEC filings (by transaction date) for TARA within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Jan 23/24 | Jan 19/24 | Bandari Jathin | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 137,000 | |
Jan 23/24 | Jan 19/24 | Bandari Jathin | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -2,879 | $1.91 |
Jan 23/24 | Jan 19/24 | Bandari Jathin | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 23,000 | |
Jan 23/24 | Jan 19/24 | Shefferman Jesse | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 357,000 | |
Jan 23/24 | Jan 19/24 | Shefferman Jesse | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -7,803 | $1.91 |
Jan 23/24 | Jan 19/24 | Shefferman Jesse | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 59,000 | |
Jan 23/24 | Jan 19/24 | Zummo Jacqueline | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 137,000 | |
Jan 23/24 | Jan 19/24 | Zummo Jacqueline | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -3,049 | $1.91 |
Jan 23/24 | Jan 19/24 | Zummo Jacqueline | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 23,000 | |
Jan 23/24 | Jan 19/24 | Fabbio Patrick | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 131,000 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for TARA within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Jan 23/24 | Jan 19/24 | Bandari Jathin | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 137,000 | |
Jan 23/24 | Jan 19/24 | Bandari Jathin | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -2,879 | $1.91 |
Jan 23/24 | Jan 19/24 | Bandari Jathin | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 23,000 | |
Jan 23/24 | Jan 19/24 | Shefferman Jesse | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 357,000 | |
Jan 23/24 | Jan 19/24 | Shefferman Jesse | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -7,803 | $1.91 |
Jan 23/24 | Jan 19/24 | Shefferman Jesse | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 59,000 | |
Jan 23/24 | Jan 19/24 | Zummo Jacqueline | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 137,000 | |
Jan 23/24 | Jan 19/24 | Zummo Jacqueline | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -3,049 | $1.91 |
Jan 23/24 | Jan 19/24 | Zummo Jacqueline | Direct Ownership | Common Stock | A - Grant, award or other under Rule 16b-3(d) | 23,000 | |
Jan 23/24 | Jan 19/24 | Fabbio Patrick | Direct Ownership | Stock Option (Right to Buy) | A - Grant, award or other under Rule 16b-3(d) | 131,000 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |
Madrigal Pharmaceuticals (OQ:MDGL) |